Naphazoline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Conjunctival decongestant As 0.1% soln: Instill 1-2 drops onto conjunctival sac 3-4 hrly, as needed. Minor eye irritation As 0.012% soln: Instill 1-2 drops into affected eye(s) bid or tid. Nasal Nasal decongestant As 0.05% soln: 1-2 drops in each nostril up to 6 hrly for 3 days.
Dosage Details
Nasal
Nasal congestion
Adult: As 0.05% soln: 1-2 drops in each nostril up to 6 hrly for 3 days.
Child: ≥12 yr Same as adult dose.

Ophthalmic
Conjunctival decongestant
Adult: As 0.1% soln: Instill 1-2 drops onto conjunctival sac 3-4 hrly, as needed.

Ophthalmic
Minor eye irritation
Adult: As 0.012% soln: Instill 1-2 drops into affected eye(s) bid or tid.
Child: ≥12 yr Same as adult dose.
Contraindications
Ophth: Narrow-angle glaucoma, corneal damage, acute iritis and other serious eye disease.
Special Precautions
Patient w/ CV disease, HTN, DM, hyperthyroidism, local infection or injury. Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Rebound vasodilation or congestion (prolonged/frequent use).
Nervous: Nervousness, headache, drowsiness, dizziness, weakness.
GI: Nausea.
CV: Cardiac irregularities, HTN.
Resp: Burning, stinging, sneezing, increased discharge (nasal).
Endocrine: Hyperglycaemia.
Ophthalmologic: Mydriasis, ocular hyperaemia, increased redness, irritation, discomfort, blurred vision, punctuate keratitis, lacrimation, increased intraocular pressure.
Dermatologic: Sweating.
Patient Counseling Information
This drug may cause drowsiness, temporary blurred vision, and transient mydriasis, if affected, do not drive or operate machinery. Remove contact lenses prior to ophth admin and reinsert after 10-15 min.
Drug Interactions
Potentially Fatal: May cause hypertensive crisis w/ MAOI(s).
Action
Description: Naphazoline is an alpha adrenergic receptor agonist which causes vasoconstriction by stimulating arterioles of the conjunctiva and nasal mucosa thus reducing swelling, redness and discomfort when applied to mucous membranes.
Onset: Conjunctival vasoconstriction: W/in 10 min.
Duration: 2-6 hr.
Pharmacokinetics:
Absorption: May be absorbed systemically.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store below 25°C.
ATC Classification
S01GA01 - naphazoline ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.
R01AA08 - naphazoline ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants.
Disclaimer: This information is independently developed by MIMS based on Naphazoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Albalon
  • Naphazoline Jean-Marie Eye/Nose Drops
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in